Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bribery and corruption in the pharma industry: what the law says

This article was originally published in Scrip

Executive Summary

A recent exposé of National Health Service (NHS) staff in the UK allegedly accepting financial inducements and lavish hospitality from pharmaceutical companies suggests that despite high-profile enforcement cases in recent years, the pharmaceutical industry still has work to do to ensure all bribery and corruption in connection with the promotion of medicinal products has been eradicated. Consequently, the industry will face increasing pressure and scrutiny to demonstrate it has robust policies in place to monitor compliance and mitigate the risk of bribery and corruption.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts